RSIP Vision Introduces AI-Based Tool for Coronary Artery Analysis and Intervention Planning

February 16, 2021—RSIP Vision, a medical imaging company focused on artificial intelligence and computer vision solutions, announced a new coronary artery segmentation tool.

According to the company, the fully automated, deep–learning-based technology provides a quick, robust, and accurate three-dimensional (3D) model of coronary artery anatomy to enable precise measurements of the artery length and diameter at any point.

RSIP Vision stated that its new tool enhances image-based assessments of coronary artery function and diagnosis of conditions, such as stenosis. It also provides information to physicians for advanced procedure planning, including navigation planning, stent selection, and stent positioning. Other benefits include reduced procedural risks to the patient; comprehensive 3D modeling of all vessels; shorter procedure time; and increase ability to make quick and accurate clinical decisions.

This new module was designed to better visualize artery structure, measure the vessel dimensions in points-of-interest, and enable accurate, image-based fractional flow reserve measurements. Additional modules can show artery modification caused by stent placement or place a virtual stent in the desired position within the coronary artery. These uses replace invasive cardiac measurements and give the physician a better preprocedure planning tool for stent selection, stated the company.

Cardiac surgeon David Yakobi, MD, commented in the company’s announcement, “Proper preprocedural planning is paramount for any invasive cardiac intervention, especially in percutaneous coronary intervention (PCI). Any automated technology that eliminates human error and bias contributors has the potential to augment procedural success, increase stent patency rate in the long-run and avoid unnecessary consecutive interventions.

“This module from RSIP Vision will also allow us to integrate its analytical findings into the Syntax Score and classify the severity of patients’ combined coronary stenoses so the interventional cardiologist can predict the outcome of the procedure according to anatomical and pathological variables to guide the choice between PCI and CABG (coronary artery bypass surgery) and predict long-term survival.”

RSIP Vision’s new tool is vendor-neutral and available to third-party medical device and application vendors, as well as CT manufacturers. The initial version will provide coronary arteries segmentation in contrast CT scans. RSIP Vision plans to extend additional functionalities including calcification detection, support for pre-existing stents, and 3D reconstruction from two-dimensional angiography, advised the company.

Ron Soferman is founder and CEO of RSIP Vision, which is based in Jerusalem, Israel, and has a United States office in San Jose, California.